| Literature DB >> 34940614 |
Martin Osswald1,2, Dario Kohlbrenner1,2, Nora Nowak3, Jörg Spörri4,5, Pablo Sinues6,7, David Nieman8, Noriane Andrina Sievi2, Johannes Scherr5, Malcolm Kohler1,2.
Abstract
Continuous monitoring of metabolites in exhaled breath has recently been introduced as an advanced method to allow non-invasive real-time monitoring of metabolite shifts during rest and acute exercise bouts. The purpose of this study was to continuously measure metabolites in exhaled breath samples during a graded cycle ergometry cardiopulmonary exercise test (CPET), using secondary electrospray high resolution mass spectrometry (SESI-HRMS). We also sought to advance the research area of exercise metabolomics by comparing metabolite shifts in exhaled breath samples with recently published data on plasma metabolite shifts during CPET. We measured exhaled metabolites using SESI-HRMS during spiroergometry (ramp protocol) on a bicycle ergometer. Real-time monitoring through gas analysis enabled us to collect high-resolution data on metabolite shifts from rest to voluntary exhaustion. Thirteen subjects participated in this study (7 female). Median age was 30 years and median peak oxygen uptake (VO2max) was 50 mL·/min/kg. Significant changes in metabolites (n = 33) from several metabolic pathways occurred during the incremental exercise bout. Decreases in exhaled breath metabolites were measured in glyoxylate and dicarboxylate, tricarboxylic acid cycle (TCA), and tryptophan metabolic pathways during graded exercise. This exploratory study showed that selected metabolite shifts could be monitored continuously and non-invasively through exhaled breath, using SESI-HRMS. Future studies should focus on the best types of metabolites to monitor from exhaled breath during exercise and related sources and underlying mechanisms.Entities:
Keywords: breath tests; exercise testing; metabolomics; physical activity
Year: 2021 PMID: 34940614 PMCID: PMC8709070 DOI: 10.3390/metabo11120856
Source DB: PubMed Journal: Metabolites ISSN: 2218-1989
Participant characteristics.
| Characteristic | Subjects (N = 13) |
|---|---|
| Sex = male (%) | 6 (46.2) |
| Age (median [IQR]), years | 30.0 [27.0, 31.0] |
| BMI (median [IQR]), kg/m2 | 22.8 [22.3, 24.0] |
| Weight (median [IQR]), kg | 70.0 [62.5, 77.7] |
| Smoking = no (%) | 13 (100.0) |
| Spirometry | 5.3 [4.3, 6.4] |
| FVC 1 % predicted (median [IQR]) | 124.0 [110.0, 128.0] |
| FEV1 2 (median [IQR]) | 4.3 [3.7, 5.0] |
| FEV1 2 % predicted (median [IQR]) | 110.0 [106.0, 120.0] |
| FEV1/FVC 3 (median [IQR]) | 81.0 [76.0, 84.0] |
| Exercise per Week | 4.5 [2.0, 6.0] |
| Activity duration (median [IQR]), min | 150.0 [120.0, 210.0] |
| Activity intensity 4 = moderate (%) | 13 (100.0) |
| Adapted Borg scale (0–10) | 0.0 [0.0, 0.5] |
| Legs start (median [IQR]) | 1.0 [0.5, 1.0] |
| Dyspnea end (median [IQR]) | 9.5 [9.0, 10.0] |
| Legs end (median [IQR]) | 9.0 [7.5, 9.8] |
| Cardiopulmonary exercise test | 141.0 [123.0, 144.0] |
| HR 5 at VT2 7 (median [IQR]), beats per min | 168.5 [163.8, 179.0] |
| Maximal HR 5 (median [IQR]), beats per min | 185.0 [183.0, 190.0] |
| Power at VT1 6 (median [IQR]), W | 138.0 [88.0, 190.0] |
| Power at VT2 7 (median [IQR]), W | 234.5 [213.5, 296.2] |
| Maximal Power (median [IQR]), W | 290.0 [261.0, 366.0] |
| VO2max 8 (median [IQR]), mL/min/kg | 50.0 [47.0, 53.0] |
1 FVC = forced vital capacity, 2 FEV1 = forced expiratory volume in 1 s, 3 FEV1/FVC = ratio of forced vital capacity to forced expiratory volume in 1 s, 4 Activity intensity = percent with a median subjective moderate activity intensity, 5 HR = heart rate, 6 VT1 = ventilatory threshold 1, 7 VT2 = ventilatory threshold 2, 8 VO2max = maximum oxygen consumption.
Identification state of exhaled metabolites.
| Sum Formula | Compound Name | Measured Mass | Exact Mass | Mass Error | Identified Based on | Course of Metabolites during Exercise 3 |
|---|---|---|---|---|---|---|
| C6H12O6 | hexose | 179.0562 | 179.0556 | 3.56 | exact mass & pathway mapping, |
|
| C5H10O4 | deoxypentose | 133.0507 | 133.0501 | 4.63 | exact mass & pathway mapping |
|
| C5H10O5 | pentose | 149.0455 | 149.0450 | 3.37 | exact mass & pathway mapping, |
|
| C3H4O3 | pyruvate | 87.0088 | 87.0082 | 6.68 | exact mass & pathway mapping |
|
| C2H4O2 | glycolaldehyde | 59.0139 | 59.0133 | 10.09 | exact mass & pathway mapping |
|
| C3H6O4 | glycerate | 105.0193 | 105.0188 | 4.92 | exact mass & pathway mapping |
|
| C3H4O4 | hydroxypyruvate | 103.0037 | 103.0031 | 5.5 | exact mass & pathway mapping |
|
| C2H2O3 | glyoxylate | 72.9931 | 72.9926 | 7.28 | exact mass & pathway mapping |
|
| C2H2O4 | oxalate | 88.9881 | 88.9875 | 6.93 | exact mass & pathway mapping |
|
| C2H3O3 | glycolate | 75.0088 | 75.0082 | 7.75 | exact mass & pathway mapping |
|
| C2H4NO2 | glycine | 74.0248 | 74.0242 | 8.06 | exact mass & pathway mapping |
|
| C4H6O3 | acetoacetate | 101.0244 | 101.0239 | 5.26 | exact mass & pathway mapping |
|
| C4H8O3 | hydroxybutyrate | 103.0401 | 103.0395 | 5.64 | exact mass & pathway mapping | Constant |
| C4H4O5 | oxaloacetate | 130.9986 | 130.9980 | 4.21 | exact mass & pathway mapping, |
|
| C4H6O5 | malate | 133.0143 | 133.0137 | 4.52 | exact mass & pathway mapping, |
|
| C4H4O4 | fumarate | 115.0037 | 115.0031 | 4.93 | exact mass & pathway mapping, |
|
| C4H6O4 | succinate | 117.0194 | 117.0188 | 5.27 | exact mass & pathway mapping, |
|
| C5H6O5 | oxoglutarate | 145.0142 | 145.0137 | 3.46 | exact mass & pathway mapping, |
|
| C6H7NO4 | 2-aminomuconate | 156.0302 | 156.0297 | 3.32 | exact mass & pathway mapping |
|
| C6H8O5 | oxoadipate | 159.0299 | 159.0293 | 3.47 | exact mass & pathway mapping |
|
| C8H7NO3 | formylanthranilate | 164.0353 | 164.0348 | 3.24 | exact mass & pathway mapping |
|
| C7H7NO2 | anthranilate | 136.0404 | 136.0399 | 4.02 | exact mass & pathway mapping |
|
| C6H7NO3 | 2-aminomuconate | 140.0353 | 140.0348 | 3.8 | exact mass & pathway mapping |
|
| C7H7NO3 | 3-hydroxyanthranilate | 152.0353 | 152.0348 | 3.5 | exact mass & pathway mapping |
|
| C6H5NO2 | picolinate | 122.0248 | 122.0242 | 4.89 | exact mass & pathway mapping |
|
| C3H8O3 | glycerole | 91.0401 | 91.03952 | 6.38 | exact mass & pathway mapping |
|
| C12H24O2 | dodecanoic acid | 199.1705 | 199.1698 | 3.49 | exact mass & pathway mapping |
|
| C14H28O2 | tetradecanoic acid | 227.2018 | 227.2011 | 3.06 | exact mass & pathway mapping |
|
| C18H36O2 | octadecanoic acid | 283.2643 | 283.2637 | 2.1 | exact mass, and |
|
| C16H32O2 | hexadecanoic acid | 255.2329 | 255.2324 | 1.94 | exact mass, and |
|
| C10H20O3 | hyroxydecanoic acid | 187.1341 | 187.1334 | 3.64 | exact mass and |
|
| C10H16O3 | oxodecenoic acid | 183.1028 | 183.1021 | 3.72 | exact mass |
|
| C12H20O3 | oxododecenoic acid | 211.1340 | 211.1334 | 2.75 | exact mass |
|
1 (M-H)—deprotonated molecule; 2 ppm—parts per million; 3 courses between start on ramp and maximal ventilatory oxygen uptake.
Figure 1Metabolic pathways map. Metabolites that were identified in exhaled breath are marked with dark colour, while lighter colors are used for unidentified metabolites that demarcate important points in the pathways. Pathways including metabolites that decreased significantly between the start of the ramp and VO2max are: (A): blue for glyoxylate metabolism; (B): yellow for TCA cycle; and (C): grey-blue for tryptophan metabolism. Trends for changes in metabolite intensities are marked with arrows. Furthermore, (D): glycolysis is marked in green, lipid metabolism in brown, and ketone pathway in red. Summary data for each identified metabolite are represented with box plots (with median, quartiles, maxima and outliers) using intensities for all subjects from the start on the ramp to VO2max. Continuous intensity data over time are represented from one sample subject (subject 6).
Figure 2Intensity data over time from one sample subject (subject 6). Solid vertical lines represent the start on the ramp, dashed vertical lines represent VO2max. The left y-axis represents the ketone bodies in (A) and hydroxybutyrate in (B,C), respectively. The right y-axis represents the other metabolites. (A): Hydroxybutyrate (OHB), acetoacetate, and fragments; (B): OHB, hexose and deoxypentose; (C): OHB, stearate, palmitate, myristate and laurate; (D): OHB, hydroxydecenoate, oxodecanoate and oxodecenoate.